NorrDia Further Enhances Renal and Acute Therapies Portfolio with agreement to acquire Bellco
January 16, 2026
Transaction Reinforces Commitment to Patients Worldwide and Supports NorrDia’s Long-Term Growth Strategy
NorrDia, through its special purpose vehicle TYHC International Ltd., has entered into a definitive agreement with Mozarc Medical to acquire Mozarc’s global Renal In-Center and Adult Acute Care businesses and the operating legal entities including Bellco S.r.l. (Italy) and its subsidiaries, Laboratoire Soludia SARL (France) and Bellco Hoxen (China).
Bellco is a globally recognized renal care brand with a strong legacy in hemodialysis (HD) and continuous renal replacement therapy (CRRT). The acquisition strengthens NorrDia’s competitiveness across acute and chronic renal care, expands its global therapy offerings, and complements its existing dialysis and CRRT portfolio.
Building on rapid growth and the successful acquisition of Nikkiso’s global CRRT business early February 2025, NorrDia has become one of the top three global players in renal acute care. The addition of Bellco acquisition shall further enhance NorrDia’s global platform and supports its long-term vision to support healthcare professionals in delivering reliable, high-quality therapies to renal patients worldwide
The transaction is expected to be closed in Q2 2026. Following closing, NorrDia will assume responsibility for Bellco’s R&D and operations in Italy, France, and China, as well as its global commercial activities.
NorrDia looks forward to welcoming Bellco’s customers, partners, and employees and to shaping the future of renal care together.
All for the patient. All for our customers. A commitment upheld for decades — our journey continues.